Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Cagrilintide represents a novel approach to obesity management
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated
